BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ceptaris Therapeutics, Inc. Secures $10 Million in Series D-1 Financing


6/5/2012 7:36:17 AM

MALVERN, Pa.--(BUSINESS WIRE)-- Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that it has raised $10 million through a Series D-1 private placement of preferred stock. This financing includes prior investors, Vivo Ventures, Palo Alto Investors, Burrill & Company, Aperture Venture Partners, Osage and BioAdvance, plus new investor, Third Point, LLC.

"We believe that our proprietary mechlorethamine gel will be an important new treatment option and this latest round of financing provides Ceptaris additional capital for ongoing activities," said Stephen Tullman, President and CEO at Ceptaris. "We appreciate the commitment of all of our investors and welcome Third Point, LLC, a valued investor familiar with the management team from an earlier investment in Ception Therapeutics."

Prior to the financing, Ceptaris received a Complete Response Letter from the Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The Company is working with the FDA to address the Agency’s requests.

The funding will be used for operational expenses, including activities related to addressing the FDA’s requests.

About Ceptaris Therapeutics

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris's investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer. Please visit www.ceptaris.com for more information.

Contact:

Sam Brown Inc.

Mike Beyer, 773-463-4211

beyer@sambrown.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES